DEVA Deva Holding A.S.
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; systemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and blood forming organs, cardiovascular system, musculoskeletal system, nervous system, alimentary tract and metabolism, respiratory system, urinary systems, connective tissue, and sensory organs. In addition, the company offers various products in sterile and non-sterile forms, including liquids, semi-solids, solids, cephalosporins, penicillin, hormone and inhalation products, solid and liquid oncology, animal health products, active pharmaceutical ingredients, ampoules, liquid and lyophilized vials, eye drops, and medical ampoules for sterile injectable products, as well as cologne. It also exports its products to approximately 60 countries. The company was incorporated in 1958 and is based in Istanbul, Turkey. Deva Holding A.S. is a subsidiary of Eastpharma S.à R.L.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Deva Holding A.S. (IST: DEVA)
›
Deva Holding A.S. (IST: DEVA) is listed on Borsa Istanbul, where its shares trade in TRY. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 3,079 employees.
The shares were at 71.40 TRY on 19 November 2026, up 14.8% over 52 weeks. Its 52-week range is 57.50 TRY to 109.30 TRY: the price is 34.7% below the high and 24.2% above the low.
Its market capitalisation is 14.28B TRY.
Deva Holding A.S. reports return on equity of -3.1%, an operating margin of 10.0% and revenue up 5.7% year over year.
Its debt exceeds its cash by 3.91B TRY, a debt-to-equity ratio of 0.23. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.